About BigHat Biosciences
BigHat Biosciences is a biotechnology company that develops safer, more effective antibody therapies using an integrated platform combining machine learning, synthetic biology, and high-throughput wet-lab automation (the Milliner™ platform). The company serves biopharma partners and maintains an internal pipeline of therapeutic candidates targeting challenging diseases in oncology, inflammation, and immunology. Its AI/ML-driven platform enables rapid design, synthesis, and optimization of next-generation antibody formats including multispecifics, VHH nanobodies, and antibody-drug conjugates (ADCs).
Company details
Funding
Total raised
$100M
Last stage
Growth
Investors
Founders
Mark DePristo
University of Cambridge biochemistry Ph.D. and former Head of Genomics for Google AI. Co-founded BigHat Biosciences in 2019.
Peyton Greenside
Co-founded BigHat Biosciences in 2019, identifying antibody discovery as a key biomedicine challenge ripe for AI/ML integration with high-throughput wet-lab experiments.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.